(NYSE: EBS) Emergent Biosolutions's forecast annual revenue growth rate of -7.24% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 3.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.84%.
Emergent Biosolutions's revenue in 2025 is $965,400,000.On average, 2 Wall Street analysts forecast EBS's revenue for 2025 to be $44,666,038,006, with the lowest EBS revenue forecast at $43,874,395,899, and the highest EBS revenue forecast at $45,457,680,113. On average, 2 Wall Street analysts forecast EBS's revenue for 2026 to be $51,622,284,314, with the lowest EBS revenue forecast at $38,382,565,363, and the highest EBS revenue forecast at $64,862,003,265.
In 2027, EBS is forecast to generate $35,697,984,040 in revenue, with the lowest revenue forecast at $35,697,984,040 and the highest revenue forecast at $35,697,984,040.